Gergen Mark J 4
4 · Poseida Therapeutics, Inc. · Filed Dec 11, 2024
Insider Transaction Report
Form 4
Gergen Mark J
DirectorExecutive Chairman
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2024-12-10−30,000→ 96,372 totalExercise: $2.78Exp: 2028-03-01→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2024-12-10$2.78/sh+30,000$83,430→ 681,291 total - Sale
Common Stock
2024-12-10$9.46/sh−30,000$283,866→ 651,291 total
Footnotes (3)
- [F1]The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.44 to $9.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock option is fully vested and exerciseable.